logo
Breakthrough in search for HIV cure leaves researchers ‘overwhelmed'

Breakthrough in search for HIV cure leaves researchers ‘overwhelmed'

The Guardiana day ago

A cure for HIV could be a step closer after researchers found a new way to force the virus out of hiding inside human cells.
The virus's ability to conceal itself inside certain white blood cells has been one of the main challenges for scientists looking for a cure. It means there is a reservoir of the HIV in the body, capable of reactivation, that neither the immune system nor drugs can tackle.
Now researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne, have demonstrated a way to make the virus visible, paving the way to fully clear it from the body.
It is based on mRNA technology, which came to prominence during the Covid-19 pandemic when it was used in vaccines made by Moderna and Pfizer/BioNTech.
In a paper published in Nature Communications, the researchers have shown for the first time that mRNA can be delivered into the cells where HIV is hiding, by encasing it in a tiny, specially formulated fat bubble. The mRNA then instructs the cells to reveal the virus.
Globally, there are almost 40 million people living with HIV, who must take medication for the rest of their lives in order to suppress the virus and ensure they do not develop symptoms or transmit it. For many it remains deadly, with UNAids figures suggesting one person died of HIV every minute in 2023.
It was 'previously thought impossible' to deliver mRNA to the type of white blood cell that is home to HIV, said Dr Paula Cevaal, research fellow at the Doherty Institute and co-first author of the study, because those cells did not take up the fat bubbles, or lipid nanoparticles (LNPs), used to carry it.
The team have developed a new type of LNP that those cells will accept, known as LNP X. She said: 'Our hope is that this new nanoparticle design could be a new pathway to an HIV cure.'
When a colleague first presented test results at the lab's weekly meeting, Cevaal said, they seemed too good to be true.
'We sent her back into the lab to repeat it, and she came back the next week with results that were equally good. So we had to believe it. And of course, since then, we've repeated it many, many, many more times.
'We were overwhelmed by how [much of a] night and day difference it was – from not working before, and then all of a sudden it was working. And all of us were just sitting gasping like, 'wow'.'
Further research will be needed to determine whether revealing the virus is enough to allow the body's immune system to deal with it, or whether the technology will need to be combined with other therapies to eliminate HIV from the body.
The study is laboratory based and was carried out in cells donated by HIV patients. The path to using the technology as part of a cure for patients is long, and would require successful tests in animals followed by safety trials in humans, likely to take years, before efficacy trials could even begin.
'In the field of biomedicine, many things eventually don't make it into the clinic – that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality,' stressed Cevaal. 'But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus.
'So from that point of view, we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans.'
Dr Michael Roche of the University of Melbourne and co-senior author of the research, said the discovery could have broader implications beyond HIV, with the relevant white blood cells also involved in other diseases including cancers.
Dr Jonathan Stoye, a retrovirologist and emeritus scientist at the Francis Crick Institute, who was not involved in the study, said the approach taken by the Melbourne team appeared be a major advance on existing strategies to force the virus out of hiding, but further studies would be needed to determine how best to kill it after that.
He added: 'Ultimately, one big unknown remains. Do you need to eliminate the entire reservoir for success or just the major part? If just 10% of the latent reservoir survives will that be sufficient to seed new infection? Only time will tell.
'However, that does not detract from the significance of the current study, which represents a major potential advance in delivery of mRNA for therapeutic purposes to blood cells.'
Prof Tomáš Hanke of the Jenner Institute, University of Oxford, disputed the idea that getting RNA into white blood cells had been a significant challenge. He said the hope that all cells in the body where HIV was hiding could be reached in this way was 'merely a dream'.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASKAP J1832: Scientists discovers mysterious pulsating star in space
ASKAP J1832: Scientists discovers mysterious pulsating star in space

BBC News

time43 minutes ago

  • BBC News

ASKAP J1832: Scientists discovers mysterious pulsating star in space

Scientists say they've spotted a mysterious object in space behaving in a very strange star, which has been named ASKAP J1832, is acting unlike anything seen before, according to Nasa around 15,000 light years from Earth, it is pulsing every 44 even more strange is that it is doing it with both radio waves and X-rays. What did scientists find? A team of astronomers looked at data from Nasa's space-based Chandra X-ray Observatory and the Square Kilometre Array Pathfinder (ASKAP) radio telescope in Australia to study the discovered object, which has been called ASKAP found that the star belongs to a class of objects called "long period radio transients" - that means it sends out radio waves of different levels over tens of minutes - in this case every 44 they also found that it is also sending X-rays every 44 minutes to Nasa, this combination of factors is "unlike anything astronomers have seen in the Milky Way galaxy."Experts are trying to work out what type of object ASKAP J1832, however they think it might be one of two could be a magnetar - which is a neutron star with an extremely strong magnetic field, with an age of more than half a million it could also be possibly an unusual white dwarf star which has a companion star.

Contraceptives for poorest countries stuck in warehouses after US aid cuts
Contraceptives for poorest countries stuck in warehouses after US aid cuts

Reuters

time2 hours ago

  • Reuters

Contraceptives for poorest countries stuck in warehouses after US aid cuts

LONDON, June 5 (Reuters) - Contraceptives that could help prevent millions of unwanted pregnancies in some of the world's poorest countries are stuck in warehouses because of U.S. aid cuts and could be destroyed, two aid industry sources and one former government official said. The stock, held in Belgium and Dubai, includes condoms, contraceptive implants, pills and intrauterine devices, together worth around $11 million, the sources told Reuters. It has been stalled since the Trump administration started cutting foreign aid as part of its 'America First' policy in February, as the U.S. government no longer wants to donate the contraceptives or pay the costs for delivery, they said. The U.S. Agency for International Development (USAID) has instead asked the contractor managing its health supply chain, Chemonics, to try to sell it, two of the sources said. An internal USAID memo, sent in April, said a quantity of contraceptives was being kept in warehouses and they should be "immediately transferred to another entity to prevent waste or additional costs". A senior U.S. State Department official told Reuters no decision had been made about the future of the contraceptives. They did not respond to questions about the reasons why the contraceptives were in storage or the impact of the U.S. aid cuts and delays. A spokesperson for Chemonics said they were unable to comment on USAID's plans, but added that the company is working with clients to deliver life-saving aid globally and would continue to support the U.S. government's global health supply chain priorities. The stock represents just under 20% of the supply of contraceptives bought annually by the U.S. for donation overseas, a former USAID official told Reuters. Selling or donating the contraceptives has been challenging, according to the former USAID official, although talks are ongoing. Another option on the table is destroying it, at a cost of several hundred thousand dollars. As time goes on, shelf-lives will also become an issue, one of the sources said. The sources told Reuters that one of the key delays is a lack of response from the U.S. government about what should be done with the stock. It had been destined largely for vulnerable women in sub-Saharan Africa, including young girls who face higher health risks from early pregnancy as well as those fleeing conflict or who otherwise could not afford or access the contraceptives, the sources added. The condoms also help stop the spread of HIV, the former USAID official said. "We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on," said Karen Hong, chief of UNFPA's supply chain. She said the agency is now working on Plan B to help fill critical supply gaps.

What you need to know about the new Covid strain NB.1.8.1 detected in the UK
What you need to know about the new Covid strain NB.1.8.1 detected in the UK

The Independent

time3 hours ago

  • The Independent

What you need to know about the new Covid strain NB.1.8.1 detected in the UK

A new Covid -19 variant, NB.1.8.1, is spreading globally, accounting for over 10 per cent of infections and has been confirmed in the UK. The WHO has designated NB.1.8.1 as a 'variant under monitoring,' noting it may spread more easily but doesn't appear to cause more severe illness than previous variants. First recognised in January 2025, NB.1.8.1 has spread to the US, Australia, Thailand, China, and Hong Kong, with initial cases registered in late April, according to GISAID data. Experts suggest NB.1.8.1 can infect cells more efficiently and may trigger gastrointestinal symptoms, while common symptoms align with typical Omicron subvariants like fatigue, fever, and sore throat. Current Covid jabs are expected to remain effective against the NB.1.8.1 variant, protecting against severe illness, though the true number of infections is difficult to ascertain due to decreased testing.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store